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Background: Thyroid dysfunction (TD) and metabolic syndrome (MetS) are known risk factors for atherosclerotic cardiovascu-
lar disease (ASCVD). TD is risk factor for ASCVD mediated by the effects of thyroid hormones on lipid metabolism and blood 
pressure hence the components of MetS. It is possible that coexistence of these two disease entities and unrecognized TD in pa-
tients with MetS might substantially increase ASCVD risk. Moreover, little is known about the relationship between TD and the 
components of MetS. Thus, the purpose of this study was to evaluate the pattern of TD in patients with MetS and its relationship 
with components of the MetS.
Methods: A total of 358 previously diagnosed patients with MetS were recruited in the study. The thyroid function test parame-
ters were measured to classify TD at Dhulikhel Hospital-Kathmandu University Hospital, Dhulikhel, Nepal. Statistical analyses 
were performed using SPSS version 16.0 to evaluate pattern and relationship. 
Results: The overall prevalence of TD in patients with MetS was 31.84% with high prevalence of subclinical hypothyroidism 
(29.32%). We found no evidence of a relationship between TD and components of MetS, although there was significant differ-
ence in waist circumference between four groups of TD.
Conclusion: Patients with MetS had subclinical hypothyroidism greatly. Although there was no evidence of any relationship be-
tween thyroid status and all components of MetS, TD should be taken into account when evaluating and treating patients with 
MetS to reduce the impending risk. 
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INTRODUCTION 
The metabolic syndrome (MetS) is a clustering of multiple risk 
factors for atherosclerotic cardiovascular disease (ASCVD) 
such as central obesity, impaired fasting glucose (IFG) or type 2 
diabetes mellitus (T2DM), elevated triglyceride (TG), reduced 
high density lipoprotein cholesterol (HDL-C) and hyperten-
sion (HTN) [1,2]. Despite of the controversy on its definition it 
is estimated that one out of four people around the world suf-
fers from MetS [2]. The prevalence of MetS is increasing all 
over the world with different regions having individual clusters 
of epidemic risk factors, and distinctly there is an evidence for 
high prevalence of MetS in India and other South Asian coun-
tries [3-5].
 Thyroid dysfunction (TD) is defined as the altered serum thy-
roid stimulating hormone (TSH) level with normal or altered 
thyroid hormones (free triiodothyronine [fT3] and free thyrox-
ine [fT4]) [6]. TD is risk factors for ASCVD mediated by the ef-
fects of thyroid hormones on lipid and glucose metabolism and 
blood pressure, hence on components of MetS [7]. 
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 MetS and TD are both characterized by a cluster of common 
abnormalities such as abdominal obesity, hyperglycemia, HTN, 
reduced HDL-C, and elevated TG and recognized independent 
risk factors of ASCVD [7-9]. It is possible that patients suffer-
ing from both disease entities might have compounded risk. 
There are several studies regarding the prevalence of TD 
among MetS patients, the association or relationship of MetS 
and its components with TD, but the results are controversial 
[8,10]. Furthermore, when exploring the relationship between 
TD and components of MetS, most studies have focused on the 
subclinical hypothyroidism (SCH). Unrecognized TD may im-
pair metabolic control and add to cardiovascular disease risk in 
patients with MetS. A study on TD in MetS population may 
help us to know the magnitude of overlap of these two disease 
entities and may highlight the importance of thyroid function 
tests in patients with MetS. This can lead to proper planning 
and adequate management strategies, resulting in significant 
reduction in cardiovascular morbidity and mortality due to 
MetS with TD. Thus, this study was intended to evaluate the 
pattern of TD in patients with MetS and to explore the relation-
ship between TD and components of the MetS.
METHODS
We performed a cross-sectional analysis by using data from the 
study on prevalence of MetS in Dhulikhel Municipality popu-
lation, Dhulikhel, Nepal between August 2011 to September 
2013. Trained interviewers, using a structured questionnaire, 
interviewed the participants at home to obtain the information 
on sociodemographic characteristics, physical activity, smok-
ing, alcohol drinking habits, dietary characteristics, personal 
and family history of diseases and hospitalization. Patients with 
known diabetes or other endocrine disorders, patients receiv-
ing any medication that may alter thyroid functions or lipid 
levels, pregnant women, and patients with a cardiovascular dis-
ease, corticosteroid use, active liver disease, and renal dysfunc-
tion, including nephrotic syndrome were excluded.
 The participants were asked to attend the mobile examina-
tion center, where they completed additional questionnaires, 
underwent various examinations, and provided a blood sample 
during an overnight fast of 8 to 12 hours. Anthropometric mea-
surements (with measuring tape) and blood pressure measure-
ments (digital BP monitoring device; Microlife Corp., Taipei, 
Taiwan) were obtained after complete physical examination by a 
trained nurse. The blood samples were transported to the Depart-
ment of Clinical Biochemistry of Dhulikhel Hospital-Kathmandu 
University Hospital, Dhulikhel, Nepal for further processing and 
analysis. Fasting blood glucose (FBG) and lipid measurements 
(HDL-C and TG) were done on the same day while remaining se-
rum sample was immediately frozen and stored at –80°C for thy-
roid function panel tests—serum TSH, serum fT4, and serum fT3 
until analysis.
 Three hundred fifty-eight patients (232 females and 126 males) 
with MetS who fulfilled National Cholesterol Education Pro-
gram-Adult Treatment Panel III (NCEP-ATP III) modified for 
Asians criteria (three out of five criteria positive) were included in 
the study group. The age of the study participant was between 30 
to 70 years. Three hundred forty-one patients who had no fea-
tures of MetS (0 out of 5 criteria for MetS) were included in the 
control group. Written informed consent was obtained from each 
patient after full explanation of the purpose and nature of all pro-
cedures used and the Institutional Review Committee of our ter-
tiary care hospital approved the study.
Laboratory measurements
FBG, TG were measured using the enzymatic colorimetric 
method (Dialab GmbH, Neudorf, Austria), and HDL-C using 
elimination method (Gesan Production Srl, Campobello di 
Mazara TP, Italy) using a Flexor Junior autoanalyzer (Vital Sci-
entific, Spankeren, Netherlands). Serum TSH, fT4, and fT3 
measurements were made by using colorimetric enzyme-linked 
immunosorbent assay (Diagnostic Automation/Cortez Diag-
nostics Inc., Calabasas, CA, USA). The analytical sensitivity of 
TSH was 0.005 μIU/mL, for fT4 was 0.005 ng/dL, and for fT3 
was 0.05 pg/mL. Normal range for TSH was 0.4 to 4.2 μIU/mL, 
for fT4 was 0.8 to 2.0 ng/dL, and for fT3 was 1.4 to 4.2 pg/mL. 
All of the assays were routinely monitored by participation in 
external quality-control programs and using assayed chemistry 
and assayed immunoassay plus controls (Bio-Rad Lab, Hercu-
les, CA, USA).
Definitions
Definition of metabolic syndrome
For the purpose of this study, MetS was diagnosed based on 
modified Asian NCEP-ATP III panel criteria. Modified Asian 
ATP III criteria are the same as original ATP III except waist 
circumference (WC) greater than 90 cm in men and 80 cm in 
women [4]. Diagnosis requires having any three of five risk fac-
tors: abnormal WC, TG levels ≥150.0 mg/dL or pharmacolog-
ic treatment (Rx), HDL-C levels: <40.0 mg/dL in male and 
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<50.0 mg/dL in female; or Rx, blood pressure: >130 mm Hg 
systolic and >85 mm Hg diastolic or Rx, and FBG concentra-
tion >100.0 mg/dL or Rx [11].
Definition of thyroid dysfunction and euthyroid 
Subjects were stratified into one of the following five groups 
based on the guidelines for the use of thyroid function tests. (1) 
Euthyroid was defined as a normal thyroid function test. (2) 
Hyperthyroidism was defined as a TSH concentration of less 
than 0.40 µIU/mL with an elevated fT4 and fT3 level. (3) Sub-
clinical hyperthyroidism was defined as a TSH concentration 
of less than 0.40 µIU/mL with a normal fT4 and fT3 concentra-
tion. (4) Hypothyroidism was defined as a TSH concentration 
of more than 4.20 µIU/mL with an fT4 and fT3 concentration 
level below normal. (5) SCH was defined as a TSH concentra-
tion of more than 4.20 µIU/mL with a normal fT4 and fT3 con-
centration [12].
 The American Thyroid Association recommends the com-
bined use of TSH and fT4 as the most efficient combination of 
blood tests for diagnosis and follow-up of both ambulatory 
and hospitalized patients [13].
Statistical analysis
Statistical analysis was performed using SPSS version 16.0 (SPSS 
Inc., Chicago, IL, USA). The results were expressed as percentage 
to determine the pattern of TD in MetS. Baseline characteristics 
of the study participants were expressed as mean±standard 
deviation. Student t-test was used to analyze differences in 
baseline characteristics between patients with MetS and the 
control group. Pearson correlation coefficients were calculated 
to assess any significant relationship between the components 
of MetS and thyroid profile parameters (TSH and fT4 levels). 
The comparison between four categories of TD was done by 
using analysis of variance (ANOVA). Statistical significance 
was defined at P<0.05.
RESULTS
Of the 358 study subjects, 105 (29.32%) had SCH, six (1.67%) 
had hypothyroidism, three (0.83%) had subclinical hyperthy-
roidism, and 244 (68.17%) were euthyroid. Hyperthyroidism 
was not present in any of the subject. The pattern of TD in pa-
tients with MetS was shown in Fig. 1. Therefore, the overall 
prevalence of the TD was 114 (31.84 %). In the healthy control 
group, only 15 (4.40 %) had SCH, five (1.47%) had hyperthy-
roidism, one (0.29%) had hypothyroidism, one (0.29%) had 
subclinical hyperthyroidism and 319 (93.54%) were euthyroid. 
The overall prevalence of TD was 6.45% among healthy con-
trol.
 After separating the subjects by gender; 34(29.82 %) male 
subjects and 80 (70.17%) female subjects had TD. The pattern 
of TD in male subject was 28 (24.56%), four (3.50%), and two 
(1.75%) with SCH, hypothyroidism, and subclinical hyperthy-
roidism respectively. Similarly, the pattern of TD in female sub-
ject was 77 (67.54%), two (1.75%), and one (0.88%) with SCH, 
hypothyroidism and subclinical hyperthyroidism, respectively.
 Differences between anthropometric and biochemical pa-
rameters between patient with MetS and healthy control were 
tested by Student t-test. There was significant differences in the 
mean values for each of the components of MetS except fT3, and 
are summarized in Table 1. Thyroid function test parameters in 
both the MetS group and healthy control group were assessed 
with fT3, fT4, and TSH assay. TSH was significantly higher in 
the MetS group than in the control group, fT4 was lower in the 
control group but there was no significant difference in levels of 
fT3 in both groups.
 The relationship of TSH and fT4 levels with the presence of 
MetS components was assessed using Pearson correlation co-
efficients analysis and is shown in Table 2. Increased FBS was 
positively related with high TSH levels but were not statistical-
ly significant, while increased WC, systolic and diastolic blood 
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pressure were negatively related with higher TSH but again 
were not statistically significant. Similarly, increased WC, sys-
tolic and diastolic blood pressure, and FBG were positively re-
lated with high fT4 levels but were not statistically significant, 
while TG was negatively related with higher fT4 but again was 
not statistically significant.
 The results for comparison of anthropometric and biochem-
ical parameters between the four categories of TD was done by 
using ANOVA but there was no significant differences in com-
ponents of MetS between four groups except WC and were 
shown in Table 3.
DISCUSSION
Our study showed that the prevalence of TD in patients with 
MetS was 31.84% and its pattern showed high prevalence of 
SCH (29.32%) followed by hypothyroidism (1.67%) and sub-
clinical hyperthyroidism (0.83%).
 The above results are in agreement with previous studies 
showing an association between MetS and TD [9,14-21]. A 
study by Meher et al. [14] showed a high prevalence of SCH 
(22%) and overt hypothyroidism (4%) in the MetS group. A 
study by Shantha et al. [9] in India has shown a high prevalence 
Table 2. Correlation between components of MetS with levels 




β Siga β Siga
SBP, mm Hg 0.098 0.233 –0.001 0.986
DBP, mm Hg 0.036 0.662 –0.061 0.459
WC, cm 0.255 0.002 –0.122 0.136
FBG, mg/dL 0.077 0.346 0.082 0.319
TG, mg/dL –0.050 0.546 –0.103 0.207
HDL-C, mg/dL 0.026 0.750 0.070 0.395
MetS, metabolic syndrome; fT4, free thyroxine; TSH, thyroid stimu-
lating hormone; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; WC, waist circumference; FBG, fasting blood glucose; TG, 
triglyceride; HDL-C, high density lipoprotein cholesterol.
aCorrelation is significant at the 0.05 level.
Table 1. Anthropometric and biochemical parameters for pa-
tient with metabolic syndrome and healthy control subjects
Parameter Patient with MetS group (n=358)
Healthy control 
group (n=341) P value
Age, yr 30–70 26–70 -
SBP, mm Hg 136.953±17.738 124.530±17.969 0.000
DBP, mm Hg 89.337±10.176 83.009±10.209 0.000
WC, cm 84.317±11.181 77.090±8.901 0.000
FBG, mg/dL 130.046±46.385 109.653±29.356 0.000
TG, mg/dL 233.774±132.273 148.469±94.911 0.000
HDL-C, mg/dL 37.344±4.267 42.207±4.897 0.000
fT3, pg/mL 2.145±0.958 2.271±0.788 0.135
fT4, ng/mL 1.936±0.742 1.227±0.320 0.000
TSH, µIU/mL 5.855±9.047 2.127±1.127 0.000
Values are presented as group range or mean±standard deviation. 
P<0.05 from the student t-test of the measured variables between 
MetS and control group.
MetS, metabolic syndrome; SBP, systolic blood pressure; DBP, dia-
stolic blood pressure; WC, waist circumference; FBG, fasting blood 
glucose; TG, triglyceride; HDL-C, high density lipoprotein cholester-
ol; fT3, free triiodothyronine; fT4, free thyroxine; TSH, thyroid stim-
ulating hormone.







(n=3) F value P value
SBP, mm Hg 136.813±16.988 135.882±19.097 135.000±8.366 163.333±15.275 2.362 0.074
DBP, mm Hg 89.890±10.592 88.039±10.003 90.000±6.324 93.333±5.773 0.524 0.667
WC, cm 85.868±11.397 83.862±9.651 67.666±6.055 78.333±10.503 5.851 0.001
FBG, mg/dL 131.087±50.966 130.019±41.262 120.833±12.765 117.333±31.021 0.166 0.919
TG, mg/dL 236.142±137.223 240.176±130.455 153.675±77.443 213.333±56.888 0.804 0.494
HDL-C, mg/dL 37.384±4.466 37.137±4.010 39.500±4.037 35.333±2.081 0.771 0.512
Values are presented as mean±standard deviation. F value and P value derived from one-way analysis of variance that used to evaluate in the 
four groups.
SBP, systolic blood pressure; DBP, diastolic blood pressure; WC, waist circumference; FBG, fasting blood glucose; TG, triglyceride; HDL-C, 
high density lipoprotein cholesterol.
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of SCH (21.90%) and overt hypothyroidism (7.40%) in patients 
with MetS. A recent study in Taiwan by Wang et al. [20] report-
ed that TD was present in 7.21% of Taiwan MetS patients. This 
study had shown 4.55% had SCH and 2.64% had subclinical hy-
perthyroidism [20]. Yet, another study in Taiwan by Lai et al. 
[21] showed that the overall prevalence of TD was 7.60% with 
2.10% to be subclinical hypothyroid and 5.50% to be subclinical 
hyperthyroid patients. Another study by Uzunlulu et al. [22] in 
Turkey had shown SCH prevalence to be 16.40% in the MetS 
group. However this study did not address patients with overt 
hypothyroidism and all observations were with SCH patients 
only [22].
 Many studies looking at the association of MetS with TD has 
found more SCH, rather than overt hypothyroidism. In contrast 
to our finding a study in India by Agarwal et al. [8] of the seven-
ty six patients with MetS, 78.0% had TD with 53.0% to be SCH 
and 25.0% had overt hypothyroidism. Similarly, Jayakumar [23] 
found that out of 120 patients who were diagnosed to have 
MetS, thyroid functions were normal in 48 patients, 18 patients 
had hypothyroidism, 52 had SCH, and two had subclinical hy-
perthyroidism. Hypothyroidism and SCH were present in 60% 
of patients with MetS [23]. Yet another study by Ogbera et al. 
[24] in Nigeria showed the proportion of subjects with hypothy-
roidism, euthyroidism and hyperthyroidism who had MetS was 
40.0%, 42.0%, and 24.0%, respectively.
 Our study revealed that the prevalence of TD was more among 
the females with MetS than those among male subjects, which is 
consistent with previous reports [2,9,17,19,22,24].
 There was significant difference in the mean values for each 
anthropometric and biochemical parameters among patients 
with MetS and healthy control subjects; only fT3 was not sig-
nificantly altered; thus, TD was related with all the components 
of MetS. These findings were similar to those obtained by Kota 
et al. [25] who mentioned body mass index (BMI), WC, mean 
systolic blood pressure (SBP), diastolic blood pressure (DBP), 
fasting blood glucose (FBG), total cholesterol, low density lipo-
protein cholesterol (LDL-C), TG, and TSH were significantly 
higher in MetS group compared to control group and HDL-C 
was significantly lower in study group. Yet another study done 
by Meher et al. [14] showed that the mean SBP, DBP, FBG, total 
cholesterol, LDL-C, TG, WC, and BMI were significantly high-
er and HDL-C levels were significantly lower in the MetS group 
than in the control group. Similar findings were obtained in the 
studies by Garduno-Garcia Jde et al. [18] on Hispanic popula-
tion and by Shantha et al. [9] on Chennai urban population.
 In concert with those studies, Oh et al. [26] found a signifi-
cant association between elevated TSH levels within normal 
range and the MetS. WC, systolic and diastolic blood pressure, 
and TG were significantly associated with TSH levels, though 
fasting hyperglycemia and low HDL-C levels were not signifi-
cantly associated with TSH levels [26]. Similarly, a recent study 
in Taiwan by Lai et al. [16] explored the relationship between 
serum TSH levels and components of MetS, concluding that 
even slight increases in TSH, as in SCH, may be a MetS risk 
factor; in that study, TSH levels were significantly higher in the 
MetS group than in the non-MetS group.
 Associations or relationship between TD and components 
of MetS have been suggested in previous studies and is well es-
tablished. There are several studies that have looked into the 
possibility of a relationship between the MetS and TD, but the 
results are disputed [10]. We found no evidence of a relation-
ship between thyroid status and all components of MetS in our 
study. Similar study, did not find the relationship between TSH 
and MetS as well as its components in people with subclinical 
hyperthyroidism [16]. Another study by Wang et al. [27] in a 
large healthy population receiving routine health examination, 
no statistical correlation was found between subclinical thyroid 
diseases and MetS.
 In contrast, a significant relationship between thyroid hor-
mones and the components of the MetS has also been shown 
in the study by Kim et al. [28]. A study done by Shantha et al. 
[9] concluded that although thyroid hormone significantly af-
fected each component of MS, there was no relationship be-
tween TD and euthyroid subjects. When exploring the rela-
tionship between TD and components of MetS, most studies 
have focused on the SCH.
 However, although components of MetS showed no positive 
correlation with TSH and fT4 levels, TSH was significantly high 
and fT4 was normal in patients with MetS suggesting that MetS 
may be associated with increased risk of SCH. The relationship 
or association between MetS and TD is complex and still not 
clear. The present study explores the relationship between four 
categories of TD with components of MetS, although there was 
higher prevalence of SCH in our study subjects. We found no 
significant differences in baseline characteristics between four 
groups of TD except WC.
 In other studies, they showed a significant association of SCH 
with components of MetS [29]. Similarly, the results of Shantha 
et al. [9] study, which showed the association of MetS and pri-
mary hypothyroidism in the urban population. The study by 
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Uzunlulu et al. [22] also had shown significant association of 
SCH and MetS, which do not supports our data. Therefore, pat-
tern of TD in MetS and its relationship with components varies 
in different studies. The geographic location, age, gender, diet, 
intake of iodine and other genetic, and environmental factor 
might possibly account for these discrepancies in pattern and 
relationships [2,9,30].
 Hence, the main finding of this report was the documenta-
tion of the pattern of TD in patients with MetS. The occurrence 
of the TD in patients with MetS may connote a state of “double 
jeopardy” in persons with MetS. The report extent the existing 
information on relationship between TD and the components 
of MetS. We found no evidence of a relationship between thy-
roid status and the prevalence of MetS. This study did not find 
the relationship between TSH and fT4 with MetS as well as its 
components. On the other hand, the relation between MetS 
and TD is not clearly identified yet, if it does then all observa-
tions were on  Subclinical hypothyroidism patients only.
 MetS, a complex of disorders including the abdominal obe-
sity, lipid abnormalities, HTN, and impaired fasting glucose, is 
one of the known risk factors for ASCVD. The concept of MetS 
has also been widely used for the comanagement of multiple 
cardiovascular risk factors including diabetes, HTN, and dys-
lipidemia in high risk persons for optimal outcomes [31]. The 
thyroid gland controls our metabolism through two hormones 
it produces: fT3 and fT4 [9]. MetS has been linked to thyroid 
disease due to the pathophysiology of TD on lipid and glucose 
metabolism, blood pressure, and cardiovascular dysfunction 
[21]. Considerable overlap occurs in the pathogenic mecha-
nisms of ASCVD by MetS and hypothyroidism. Unrecognized 
TD in patients MetS may impair metabolic control and add to 
ASCVD risk in patients with MetS. The prevalence of TD in 
patients with MetS was high, which indicates a possible inter-
play between thyroid status and MetS. Hence, a study on TD in 
MetS population may help us to know the magnitude of over-
lap of these two groups and may highlight the importance of 
thyroid function tests in identifying hypothyroid population 
from MetS. This can lead to proper planning and adequate 
management strategies, resulting in significant reduction in 
cardiovascular morbidity and mortality due to MetS with TD.
 The pattern and relationship of thyroid function with such 
diseases or syndromes has never been studied in Nepalese pop-
ulation. Nepal is one of the high risk populations for TD [32]. 
Hence, TD should be considered in the differential diagnosis of 
patients with MetS to avoid misdiagnosis. The prevalence of 
obesity and the MetS is rapidly increasing in South Asians resid-
ing on the Indian subcontinent (e.g., India, Pakistan, Bangla-
desh, and Nepal), leading to increased morbidity and mortality 
due to T2DM and ASCVD [4,5]. Thus, it is necessary to initiate 
early detection of these chronic diseases in underdeveloped 
countries in Asia like Nepal, so that preventive action can mini-
mize the consequences. Our findings indicate a need for a sys-
tematic approach to investigate the presence of TD when evalu-
ating and treating patients with MetS.
 There are few limitations of the present study, first is that; this 
is a cross-sectional study, a cause and effect of relationship could 
not be determined. Further cohort study is needed to evaluate 
the deleterious effect of TD on cardiovascular disease and meta-
bolic functions. Second, this study did not find the association 
between TSH and fT4 and MetS as well as its components in 
people with TD and its subforms, and the reason might be there 
were few subjects with hypothyroidism and subclinical hyper-
thyroidism. Therefore, large epidemiological studies are needed 
to evaluate the relationship between subgroups of TD in patients 
with MetS.
 In conclusion, the prevalence of TD in patients with MetS 
was high, distinctively in SCH and females were at increased 
risk. Although, thyroid hormone significantly affects each 
component of MetS, there was no relationship between TD 
and all components of MetS. There is an increased incidence 
of TD, especially elevated TSH with normal T4 and T3 in 
MetS. Furthermore the coexistence of the two disease entities 
might have substantially increase ASCVD, hence it is worth-
while to order for TSH and fT4 in all patients with MetS which 
can help in reducing the risk. 
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